drugset / Trial / NCT02769845
SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia
Completed
283 enrolled
Children's Hospital Medical Center, Cincinnati
Hospital Infantil Dr. Robert Reid Cabral · collab
Non-randomizedSingle-groupOpen-labelSupportive care
Summary
Prospective screening and treatment study for children with Sickle Cell Anemia and increased stroke risk living in the Dominican Republic.
Timeline
- Start
- 2016-03-16
- Primary completion
- 2019-07-01
- Completion
- 2022-10-01
Publications
- Nieves RM, Latham T, Marte N, Berges M, Sanchez LM, Urcuyo G, Florencio C, Gonzalez C, Del Villar P, Chen S, Ramirez D, Reyes P, Marinez M, Matos E, Jeste ND, Stuber SE, Schultz WH, Lane AC, Mena R, Ware RE. Stroke prevention in Hispanic children with sickle cell anemia: the SACRED trial. Blood Adv. 2025 Apr 22;9(8):1791-1800. doi: 10.1182/bloodadvances.2024014327.
- Jeste ND, Sanchez LM, Urcuyo GS, Berges ME, Luden JP, Stuber SE, Latham TS, Mena R, Nieves RM, Ware RE. Stroke Avoidance for Children in REpublica Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Res Protoc. 2017 Jun 2;6(6):e107. doi: 10.2196/resprot.7491.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxyurea | Other / unclassified | 20 mg/kg | — |